WENDY TAYLOR: Open Payments
NPI 1538752407 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,756 in 234 payments from 25 companies in 2025. Trend: 2023 $3,582 · 2024 $3,671 · 2025 $3,756
Food & beverage: $3,756
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 59 | $954 |
| ACADIA Pharmaceuticals Inc | 62 | $524 |
| Neurocrine BioSciences, Inc. | 25 | $423 |
| MDD US Operations, LLC | 10 | $309 |
| Genentech USA, Inc. | 10 | $244 |
| Otsuka America Pharmaceutical, Inc. | 7 | $164 |
| Biogen, Inc. | 6 | $161 |
| Novartis Pharmaceuticals Corporation | 13 | $145 |
| Amneal Pharmaceuticals LLC | 10 | $136 |
| Eisai Inc. | 5 | $100 |
Products named: NUPLAZID, QULIPTA, INGREZZA, BOTOX, Ocrevus Zunovo, Leqembi, REXULTI, KESIMPTA.
Industry payments across LA — which companies pay providers there.
